Diaceutics PLC
LSE:DXRX

Watchlist Manager
Diaceutics PLC Logo
Diaceutics PLC
LSE:DXRX
Watchlist
Price: 125.5 GBX Market Closed
Market Cap: 106.3m GBX
Have any thoughts about
Diaceutics PLC?
Write Note

Diaceutics PLC
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Diaceutics PLC
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Diaceutics PLC
LSE:DXRX
Net Issuance of Common Stock
-ÂŁ49k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Net Issuance of Common Stock
ÂŁ71.6m
CAGR 3-Years
-24%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Net Issuance of Common Stock
ÂŁ305k
CAGR 3-Years
-46%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Net Issuance of Common Stock
ÂŁ6k
CAGR 3-Years
-93%
CAGR 5-Years
-77%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Net Issuance of Common Stock
ÂŁ91k
CAGR 3-Years
-60%
CAGR 5-Years
-58%
CAGR 10-Years
-21%
No Stocks Found

Diaceutics PLC
Glance View

Market Cap
106.3m GBX
Industry
Life Sciences Tools & Services

Diaceutics Plc engages in the provision of data, data analytics and implementation services. The company is headquartered in Belfast, Northern Ireland. The company went IPO on 2019-03-21. The principal activity of the Company is data analytics and implementation services. The firm is engaged in research and development activities in drug development science, testing data and software platform development. The firm's implementation services include test standardization, test quality assessment, laboratory tech support and others. The firm has established a range of products and outsourced advisory services, which help its pharma clients to optimize and deliver their marketing and implementation strategies for companion diagnostics. The firm provides the pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network. DXRX is the diagnostic commercialization platform for precision medicine, integrating multiple pipelines of diagnostic testing data from a global network of laboratories.

DXRX Intrinsic Value
167.13 GBX
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Diaceutics PLC's Net Issuance of Common Stock?
Net Issuance of Common Stock
-49k GBP

Based on the financial report for Dec 31, 2023, Diaceutics PLC's Net Issuance of Common Stock amounts to -49k GBP.

Back to Top